# Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

> **NCT03647111** · — · UNKNOWN · sponsor: **Hunan Province Tumor Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT03647111
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03647111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03647111, "Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03647111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*